Cited by 1,999Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Open access

Bonaca, Marc P., Bhatt, Deepak L., Cohen, Marc, Steg, Philippe Gabriel, Storey, Robert F., Jensen, Eva C., Magnani, Giulia, Bansilal, Sameer, Fish, M. Polly, Im, Kyungah, Bengtsson, Olof, Ophuis, Ton Oude, Budaj, Andrzej, Theroux, Pierre, Ruda, Mikhail, Hamm, Christian, Goto, Shinya, Spinar, Jindrich, Nicolau, José Carlos, Kiss, Robert G., Murphy, Sabina A., Wiviott, Stephen D., Held, Peter, Braunwald, Eugene, Sabatine, Marc S.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1500857

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P=0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P<0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1500857

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary
Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E., Green, L. A., Hand, M. M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,348
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Authors Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Mario, C. D., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,890
Self-citation
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,802
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Self-citation
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
(2009) · The Lancet · doi:10.1016/s0140-6736(09)60503-1 · Cited by 3,675

Flagged first, then by citations

Show all 32 references

1 of the 32 references couldn’t be matched to a known paper.

Sorted by citations

Items 601–700 of 999

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence
Luca, L. D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07027-4 · Cited by 18
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events
Hara, H., Klaveren, D. V., Takahashi, K., Kogame, N., Chichareon, P., Modolo, R., Tomaniak, M., Ono, M., Kawashima, H., Wang, R., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006660 · Cited by 17
Self-citation
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial
Verdoia, M., Suryapranata, H., Damen, S. A. J., Camaro, C., Benit, E., Barbieri, L., Rasoul, S., Liew, H. B., Polad, J., Ahmad, W. A. W., et al. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02439-x · Cited by 20
Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis
Tang, B., Wang, X., Wang, X., Liu, L., & Ma, Z. (2022) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps32140 · Cited by 17
“Besides, several studies also reported more frequent discontinuation of ticagrelor due to its side effects, such as dyspnea (6,10,11).”
Background
Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease
Fanaroff, A. C., & Roe, M. T. (2016) · Drug Safety · doi:10.1007/s40264-016-0421-1 · Cited by 17
“In PEGASUS, 21,162 patients with prior MI (83 % with PCI) within 1–3 years, and who were currently tolerating aspirin, were randomized to a strategy of usual care or ticagrelor plus usual care and followed for a median of 33 months [14].”
Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials
Qaderdan, K., Vos, G.-J. A., McAndrew, T., Steg, P. G., Hamm, C. W., Hof, A. W. J. V. ’., Mehran, R., Deliargyris, E., Bernstein, D., Stone, G. W., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.08.009 · Cited by 17
“In these trials, both agents significantly reduced ischemic events, but at the cost of more bleeding events, especially non-CABG major bleeding, when compared with clopidogrel or placebo.(22,28,37) Furthermore, ticagrelor reduced mortality in the PLATO trial, and the results were consistent in elderly patients.”
BackgroundResultSelf-citation
Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice
Ye, Y., Nylander, S., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6763-9 · Cited by 17
Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis
Gupta, S. K., Belley‐Côté, E. P., Panchal, P., Pandey, A. K., Basha, A., Pallo, L. P., Rochwerg, B. N., Mehta, S. R., Schwalm, J. D., & Whitlock, R. P. (2020) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivaa115 · Cited by 18
Role of rivaroxaban in the prevention of atherosclerotic events
Sanmartı́n, M., Bellmunt-Montoya, S., Cosı́n-Sales, J., García–Moll, X., Riera‐Mestre, A., Almendro‐Delia, M., Hernández, J. L., Lozano, F., Mazón, P., & Fernández, C. S. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1637732 · Cited by 16
Risk factors and functional outcome were associated with hemorrhagic transformation after mechanical thrombectomy for acute large vessel occlusion stroke
Li, W., Xing, X., Chao, W. E. N., & Liu, H. (2022) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.20.05141-3 · Cited by 16
Efficacy and Safety of Long‐Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta‐analysis of Randomized Controlled Trials
Zhu, H., Xu, X., Fang, X., Fei, Y., Song, L., Gao, B., Tong, G., Zhou, L., Chen, T., & Huang, J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019184 · Cited by 17
Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients
Ng, A. K., Ng, P. Y., Ip, A., Ling, I. W.-H., Lam, L.-T., & Siu, C. (2022) · JACC Asia · doi:10.1016/j.jacasi.2021.12.009 · Cited by 17
The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
Smith, C. W., Harbi, M. H., Garcia‐Quintanilla, L., Rookes, K., Brown, H. C., Poulter, N. S., Watson, S. P., Nicolson, P. L. R., & Thomas, M. R. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15899 · Cited by 16
The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk
Safdar, N. Z., Kietsiriroje, N., & Ajjan, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015328 · Cited by 20
“In higher-risk subjects, DAPT is continued for up to 3 years using aspirin and low-dose ticagrelor [97].”
Background
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention
Ortega‐Paz, L., Bor, W. L., Franchi, F., van den Broek, W. W. A., Rollini, F., Giordano, S. A., Galli, M., Been, L. F., Ghanem, G., Shalhoub, A., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.03.027 · Cited by 16
The future of P2Y12 receptor antagonists
Thomas, M. R., & Storey, R. F. (2015) · Platelets · doi:10.3109/09537104.2015.1049519 · Cited by 16
Self-citation
Coronary revascularisation in older patients with non-ST elevation acute coronary syndromes
Sinclair, H., & Kunadian, V. (2016) · Heart · doi:10.1136/heartjnl-2015-307859 · Cited by 16
Developing drugs for use before, during and soon after percutaneous coronary intervention
Gargiulo, G., Moschovitis, A., Windecker, S., & Valgimigli, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1145666 · Cited by 16
“associated with significant benefits compared with aspirin alone.[44] Both dosages tested (60 mg or 90 mg twice daily) reduced the primary end point and rates of MI, with”
BackgroundResult
Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination
Elewa, H. F., Ahmed, D., & Barnes, G. D. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1571337 · Cited by 16
Update ESC-Leitlinie 2017: Duale Antiplättchentherapie
Maßberg, S., & Polzin, A. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0549-8230 · Cited by 17
“[2] Bonaca MP, Bhatt DL, Cohen M et al.”
Background
Beyond conventional secondary prevention in coronary artery disease—what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature
Kalbacher, D., Waldeyer, C., Blankenberg, S., & Westermann, D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.08.03 · Cited by 16
“In 2015, PEGASUS-TIMI 54, a double-blind, randomized, controlled, multi-center study including 21,162 patients with stable coronary artery disease (CAD), defined as history of MI (1 to 3 years earlier) were assigned to ticagrelor 90 mg bid, ticagrelor 60 mg bid or placebo in a 1:1:1-fashion (18).”
Method
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
Bergmark, B. A., Bhatt, D. L., Steg, P. G., Budaj, A., Storey, R. F., Gurmu, Y., Kuder, J., Im, K., Magnani, G., Ophuis, T. O., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020446 · Cited by 18
Self-citation
Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing
González‐Juanatey, C., Anguita-Sánchez, M. P., Barrios, V., Nuñez-Gil, I. J., Gómez-Doblas, J. J., García–Moll, X., Gormaz, C. L., Rollán-Gómez, M. J., Peral-Disdie, V., Martínez‐Dolz, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263277 · Cited by 16
“In this context, the THEMIS-PCI trial was part of a recent large phase 3 randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy and safety of ticagrelor 60 mg bid added to background acetylsalicylic acid (ASA) therapy for the prevention of MACE in this population [13].”
MethodInfluential
Ticagrelor-related gout: An underestimated side effect
Zhang, N., Zhang, Z., Yang, Y., Xu, Y., Li, G., & Liu, T. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.023 · Cited by 16
Implications of the PEGASUS-TIMI 54 trial for US clinical practice
Bradley, S. M., Hess, G. P., Stewart, P., Armstrong, E. J., Farmer, S. A., Wasfy, J. H., Valle, J. A., Sandhu, A., & Maddox, T. M. (2017) · Open Heart · doi:10.1136/openhrt-2016-000580 · Cited by 16
Antithrombotics in stable peripheral artery disease
Kaplovitch, E., Rannelli, L., & Anand, S. S. (2019) · Vascular Medicine · doi:10.1177/1358863x18820123 · Cited by 19
A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan
Li, Y., Chen, J., Lin, T., Wang, Y.-C., Wu, C., Yeh, H., Huang, C., Chang, K., Wu, C., Chen, P., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.04.007 · Cited by 17
Advances in the Detection and Management of Vulnerable Coronary Plaques
Spagnolo, M., Giacoppo, D., Laudani, C., Greco, A., Finocchiaro, S., Mauro, M. S., Imbesi, A., & Capodanno, D. (2025) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.125.015529 · Cited by 21
GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation
Koganov, E. S., Michelson, A. D., Yanachkov, I. B., Yanachkova, M. I., Wright, G. E., Przyklenk, K., & Frelinger, A. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-32797-1 · Cited by 15
Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions
Caracciolo, A., Mazzone, P., Laterra, G., Garcia-Ruiz, V., Polimeni, A., Galasso, S., Saporito, F., Carerj, S., D’Ascenzo, F., Marquis‐Gravel, G., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8112016 · Cited by 15
“Ticagrelor was also associated with a significant increase in TIMI major bleeding, but no increase in intracranial hemorrhage [43].”
Background
Nanoscale Flow Choking and Spaceflight Effects on Cardiovascular Risk of Astronauts – A New Perspective
Kumar, V. S., Choudhary, S. K., Radhakrishnan, P. K., Bharath, R. S., Chandrasekaran, N., Oommen, C., Sankar, V., Ajith, S., Mariappan, A., Thianesh, U. K., et al. (2021) · AIAA SciTech Forum · doi:10.2514/6.2021-0357 · Cited by 15
Aspirin at 120: Retiring, recombining, or repurposing?
Patrono, C., & Rocca, B. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12516 · Cited by 15
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
Kubica, J., Adamski, P., Gorog, D. A., Kubica, A., Jilma, B., Budaj, A., Siller-Matula, J. M., Gurbel, P. A., Alexopoulos, D., Badarienė, J., et al. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0118 · Cited by 15
“provide comparable clinical efficacy, with a better tolerability of treatment observed with a lower dose [3, 5].”
BackgroundSelf-citation
Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
Барбараш, О. Л., Komarov, A. L., Панченко, Е. П., Староверов, И. И., Shakhnovich, R. M., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-4-6-59 · Cited by 16
Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
Xi, Z., Li, J., Qiu, H., Guo, T., Wang, Y., Yang, L., Zheng, J., Dou, K., Xu, B., Wu, Y., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.768190 · Cited by 15
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases
Tao, L., Ren, S., Zhang, L., Liu, W., Zhao, Y., Chen, C., Mao, X., Chen, Z., & Gu, X. (2022) · Medical Science Monitor · doi:10.12659/msm.935664 · Cited by 16
Gender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes
Occhipinti, G., Greco, A., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2245331 · Cited by 16
“The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction) trial was designed to evaluate the benefit of prolonged DAPT among patients with a previous myocardial infarction (one to t…”
Method
Antiplatelet therapy around CABG: the latest evidence
Sandner, S. E., Redfors, B., & Gaudino, M. F. L. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001078 · Cited by 15
Lipoprotein(a) and Benefit of Antiplatelet Therapy
Patel, S. M., Bonaca, M. P., Morrow, D. A., Palazzolo, M. G., Jarolı́m, P., Steg, P. G., Bhatt, D. L., Storey, R. F., Sabatine, M. S., & O’Donoghue, M. L. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100675 · Cited by 15
Self-citation
Antiplatelet De-Escalation Strategies in Patients Undergoing Percutaneous Coronary Intervention
Spirito, A., Krishnan, S. L., Capodanno, D., Angiolillo, D. J., & Mehran, R. (2024) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.123.013263 · Cited by 16
Contemporary Prestroke Dual Antiplatelet Use and Symptomatic Intracerebral Hemorrhage Risk After Thrombolysis
Peng, T. J., Schwamm, L. H., Fonarow, G. C., Hassan, A. E., Hill, M., Messe, S. R., Coronado, F., Falcone, G. J., & Sharma, R. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.1312 · Cited by 15
Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications
Su, Y., Cheng, X., & Dong, Q. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12419 · Cited by 15
“Another recent trial named the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin– Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) indicated similar results with the DAPT of a novel P2Y12 receptor antagonist of ticagrelor a…”
Result
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial
Berwanger, O. B., Nicolau, J. C., Carvalho, A. C., Jiang, L., Goodman, S. G., Nicholls, S. J., Parkhomenko, A. N., Валерьевич, А. О., Tajer, C. D., Málaga, G., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.02.017 · Cited by 15
Self-citation
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation
Giustino, G., Redfors, B., Kirtane, A. J., Mehran, R., Dangas, G., Witzenbichler, B., Neumann, F., Weisz, G., Généreux, P., Maehara, A., et al. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.01.263 · Cited by 15
Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians?
Su-Yin, D. T. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.13.2.eo2 · Cited by 15
Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention
Li, J., Qiu, H., Yan, L., Guo, T., Wang, Y., Yang, L., Zheng, J., Tang, Y., Xu, B., Qiao, S., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1825364 · Cited by 15
Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
Hennigan, B., Good, R., Adamson, C., Parker, W. A., Martin, L., Anderson, L., Campbell, M. J., Serruys, P. W. J. C., Storey, R. F., & Oldroyd, K. G. (2020) · Platelets · doi:10.1080/09537104.2020.1863937 · Cited by 15
“Addition of ticagrelor to aspirin has also been shown to reduce long-term MACE in patients with prior MI who are at increased risk of further ischemic events [13].”
BackgroundSelf-citation
Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management
Guedeney, P., & Collet, J. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1722188 · Cited by 15
Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score
Würtz, M., Olesen, K. K. W., Mortensen, M. B., Eikelboom, J. W., Mohammad, M. A., Erlinge, D., Kristensen, S. D., & Mæng, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab785 · Cited by 16
Why we should not skip aspirin in cardiovascular prevention
Schrör, K. (2015) · Hämostaseologie · doi:10.5482/hamo-14-10-0048 · Cited by 14
Percutaneous Coronary Intervention: 2015 in Review
Grines, C. L., Harjai, K. J., & SCHREIBER, T. L. (2016) · Journal of Interventional Cardiology · doi:10.1111/joic.12272 · Cited by 15
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study
Nardin, M., Verdoia, M., Pergolini, P., Rolla, R., Barbieri, L., Schaffer, A., Marino, P. N., Bellomo, G., Suryapranata, H., & Luca, G. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.001 · Cited by 15
Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Sharma, A., Hai, O. Y., Garg, A., Vallakati, A., Lavie, C. J., & Marmur, J. D. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.04.001 · Cited by 15
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity
Verdoia, M., Pergolini, P., Rolla, R., Barbieri, L., Schaffer, A., Marino, P. N., Bellomo, G., Suryapranata, H., & Luca, G. D. (2017) · Angiology · doi:10.1177/0003319717736407 · Cited by 15
Secondary prevention after CABG: do new agents change the paradigm?
Paquin, A., Poirier, P., Beaudoin, J., & Piché, M. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000783 · Cited by 15
“In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor added to low-dose aspirin improved cardiovascular outcomes in high risk patients when given 1 to 3…”
Method
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events
Serebruany, V. L. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.043 · Cited by 15
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis
Giustino, G., Baber, U., Salianski, O., Sartori, S., Stone, G. W., Leon, M. B., Aquino, M. B., Stefanini, G. G., Steg, P. G., Windecker, S., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.002995 · Cited by 14
Self-citation
The year in cardiology 2015: acute coronary syndromes
Montalescot, G., & Crea, F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv686 · Cited by 14
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study)
Lemesle, G., Schurtz, G., Meurice, T., Tricot, O., Lemaire, N., Caudmont, S., Philias, A., Ketelers, R., Lamblin, N., & Bauters, C. (2016) · Cardiology · doi:10.1159/000442706 · Cited by 14
Risk of infections in patients treated with ticagrelor vs. clopidogrel: a systematic review and meta-analysis
Li, H., Feng, Q., Tsoi, M. F., Fei, Y., & Cheung, B. M. Y. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa065 · Cited by 14
Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options
Yin, D. R. P. P. C. P., & ten Berg, J. M. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01604-4 · Cited by 15
Multifocal atherosclerosis: focus on the prevention of ischemic events
Arutyunov, A. G., Батлук, Т. И., Bashkinov, R. A., & Trubnikova, M. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4808 · Cited by 15
Artificial-Intelligence-Assisted Discovery of Genetic Factors for Precision Medicine of Antiplatelet Therapy in Diabetic Peripheral Artery Disease
Yeh, C., Chou, Y.-J., Tsai, T.-H., Hsu, P. W.-C., Li, C., Chan, Y.-H., Tsai, S., Ng, S., Chou, K.-M., Lin, Y., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010116 · Cited by 14
“In the PEGASUS-TIMI 54 trial, a lower dosage of ticagrelor (60-mg twice daily) resulted in particularly favorable outcomes for CV and all-cause mortality among patients after myocardial infarction complicated with PAD [21].”
Background
Advances in the treatment of ST Elevation Myocardial Infarction in the UK
Mughal, L. H., & Sastry, S. (2022) · JRSM Cardiovascular Disease · doi:10.1177/20480040221075519 · Cited by 18
Intracoronary Application of Super-Saturated Oxygen to Reduce Infarct Size Following Myocardial Infarction
Schäfer, A., Akin, M., Diekmann, J., & König, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061509 · Cited by 16
Cardiovascular prevention in elderly patients.
Bonanad, C., Fernández-Olmo, R., García‐Blas, S., Alarcon, J. A., Díez‐Villanueva, P., Mansilla, C. R., García‐Pardo, H., Toledo, P., Ayesta, A., Pereira, E., et al. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.05.004 · Cited by 15
“Ticagrelor has been shown to be safe and effective in patients over 75 years of age, so in those patients with high ischemic risk and low bleeding risk it should be considered.([61,62]) Regarding the prolongation of dual antiplatelet therapy, the patient’s ischemic risk would be assessed one year after tolerating dual…”
Background
Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review
Oliva, A., Cao, D., Spirito, A., Nicolas, J., Pileggi, B., Kamaleldin, K. M., Vogel, B., & Mehran, R. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s391400 · Cited by 17
Decoding the role of platelets in tumour metastasis: enigmatic accomplices and intricate targets for anticancer treatments
Zhao, J., Huang, A., Zeller, J., Peter, K., & McFadyen, J. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1256129 · Cited by 14
“…mortality in patients treated with prasugrel compared to clopidogrel as part of dual antiplatelet therapy, whilst the DAPT study and PEGASUS-TIMI trial reported higher incidences of cancer-related mortality with dual antiplatelet therapy using clopidogrel and ticagrelor, respectively (137 – 139).”
Result
The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease
Khorsandi, M., Blumenthal, R. S., Blaha, M. J., & Kohli, P. (2024) · Clinical Cardiology · doi:10.1002/clc.24284 · Cited by 14
Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy
Iqbal, J., & Serruys, P. W. J. C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.02.15 · Cited by 14
“DAPT, if tolerated, should be continued for a minimum of 12 months, although evidence for longer duration is emerging (10,11).”
Background
Role of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention ― Systematic Review and Meta-Analysis ―
Misumida, N., Kobayashi, A., Kim, S. M., Abdel‐Latif, A., & Ziada, K. M. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0410 · Cited by 14
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial
Biscaglia, S., Tonet, E., Pavasini, R., Serenelli, M., Bugani, G., Cimaglia, P., Gallo, F., Spitaleri, G., Franco, A. D., Aquila, G., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182124 · Cited by 14
Is ticagrelor worth its high cost and side-effects?
Guerbaaï, R.-A., Mahata, I., Maréchaux, S., Jemtel, T. H. L., & Ennezat, P. (2018) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2018.1469371 · Cited by 15
“The modest benefit of longterm ticagrelor use was noted against placebo in the PEGASUS-TIMI54 trial and not against another P2Y12receptor antagonist [8].”
BackgroundMethodInfluential
Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention
Alomari, M., etsu.edu, H. B., Musmar, A., Momani, L. A. A., & Young, M. (2019) · Cureus · doi:10.7759/cureus.3874 · Cited by 14
Role of Gender in Dual Antiplatelet Therapy After Acute Coronary Syndrome
Mallidi, J. R., & Lata, K. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0795-5 · Cited by 14
Novel approaches to P2Y 12 inhibition and aspirin dosing
Parker, W. A., & Storey, R. F. (2020) · Platelets · doi:10.1080/09537104.2020.1714574 · Cited by 14
“Prior Heart Attack Using Ticagrelor compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS TIMI 54) trial showed that long-term DAPT with aspirin and ticagrelor (60 mg BD or 90 mg BD) significantly reduced the risk of ischemic events in higher-risk patients with a history of m…”
MethodSelf-citation
Percutaneous Coronary Intervention
Khera, S., Kolte, D. S., & Bhatt, D. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00016-4 · Cited by 14
Self-citation
Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine
Kaul, S. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.05.017 · Cited by 14
Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
Ponte-Negretti, C. I., Wyss, F., Piskorz, D. L., Santos, R. D., Villar, R., Lorenzatti, A., López-Jaramillo, P. A., Toth, P. P., Amaro, A. J. J., Rodrigo, A. K., et al. (2021) · Archivos de cardiología de México · doi:10.24875/acm.21000005 · Cited by 21
Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
Simonsson, M., Alfredsson, J., Szummer, K. E., Jernberg, T., & Ueda, P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20030 · Cited by 14
Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
Magnani, G., & Valgimigli, M. (2016) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2015:17:2 · Cited by 14
Self-citation
Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease
Humbert, X., Roule, V., Chequel, M., Fédrizzi, S., Brionne, M., Lelong‐Boulouard, V., Milliez, P., & Alexandre, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.212 · Cited by 14
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia
Rosa, G. M., Bianco, D., Valbusa, A., Massobrio, L., Chiarella, F., & Brunelli, C. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1244524 · Cited by 15
“The researchers estimated that ticagrelor could prevent 40 primary endpoint events per year at a dosage of 90 mg twice daily and 42 primary endpoint events per year at a dosage of 60 mg twice daily [46].”
BackgroundInfluential
Perioperative management of antithrombotic therapies
Yurttas, T., Wanner, P. M., & Filipovic, M. (2017) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000481 · Cited by 15
Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST‐Elevation Myocardial Infarction: Results From a Multi‐Center Randomized Trial
Spitzer, E., Frei, M., Zaugg, S., Hadorn, S., Kelbæk, H., Ostojić, M., Baumbach, A., Tüller, D., Roffi, M., Engstrøm, T., et al. (2017) · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · doi:10.1161/jaha.117.005926 · Cited by 15
Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis
Mangiacapra, F., Colaiori, I., Ricottini, E., Creta, A., Gioia, G. D., Cavallari, I., Bressi, E., Capuano, M., Barbato, E., & Sciascio, G. D. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1630-5 · Cited by 14
Comparison of drug eluting stents (DESs) and bare metal stents (BMSs) with STEMI: who received BMS in the era of 2nd generation DES?
Doshi, R. P., Shah, J., Jauhar, V., Decter, D. H., Jauhar, R., & Meraj, P. (2018) · Heart & Lung · doi:10.1016/j.hrtlng.2018.02.004 · Cited by 14
Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study
Palmero, J. G., Vidal, V., Brady, A. J. B., & Fácila, L. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.12.2 · Cited by 15
DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan
Chen, Y.-C., Lin, F., Lin, Y., Cheng, S., Lin, R.-H., Chuang, C., Sheu, J.-S., Chen, S.-M., Chang, C.-C., & Tsai, C. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0302-3 · Cited by 14
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
Petersohn, S., Pouwels, X., Ramaekers, B. L. T., ten Cate‐Hoek, A. J., & Joore, M. A. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320913380 · Cited by 14
“Probabilities on clopidogrel treatment could not be obtained from the CAPRIE trial but were informed relative to those of ticagrelor DPI.(16,20) Scenarios explore alternative bleeding risks.”
MethodInfluential
Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome
Zafeiropoulos, S., Farmakis, I. T., Κάρτας, Α., Arvanitaki, A., Pagiantza, A., Boulmpou, A., Tampaki, A., Kosmidis, D., Nevras, V., Markidis, E., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.07.046 · Cited by 14
Balancing the Risks and Benefits of Dual Platelet Inhibition
Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1502137 · Cited by 14
Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease
Parker, W. A., Gorog, D. A., Geisler, T., Vilahur, G., Sibbing, D., Rocca, B., & Storey, R. F. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa165 · Cited by 15
Self-citation
Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 14
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD
Morrison, J. T., Canonico, M. E., Anand, S. S., Patel, M. R., Debus, E. S., Nehler, M. R., Hess, C. N., Hsia, J. A., Capell, W. H., Muehlhofer, E., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.068080 · Cited by 15
Self-citation
Aspirin, Plavix, and Other Antiplatelet Medications
Ghantous, A. E., & Ferneini, E. M. (2016) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2016.06.003 · Cited by 13
Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? The PEGASUS trial in the light of the FAST-MI 2005 registry
Puymirat, É., Schiele, F., Zeller, M., Jacquemin, L., Leclercq, F., Marcaggi, X., Ferrières, J., Simon, T., & Danchin, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.191 · Cited by 13
Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome
Paravattil, B., & Elewa, H. F. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416683048 · Cited by 13
Incidence and predictors of stroke in patients discharged with the diagnosis of acute coronary syndrome
Cordero, A., Rodríguez‐Mañero, M., García‐Acuña, J. M., Bertomeu‐González, V., Agra-Bermejo, R., Cid, B., Álvarez, B. C., Bertoméu, V., & González‐Juanatey, J. R. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.082 · Cited by 13
Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study)
Liu, G. Z., Zhang, S., Sun, D. H., Shi, J. C., Bo, W. L., Wang, W. N., Zhang, C. Y., Wang, Z., Feng, W., He, M., et al. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02687-0 · Cited by 13
“The results showed that ticagrelor (60 mg twice daily) may offer a more attractive benefit-risk profile for MI patients [10].”
Background

Authors: Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., Bengtsson, O., Ophuis, T. O., Budaj, A., Theroux, P., Ruda, M., Hamm, C., Goto, S., Spinar, J., Nicolau, J. C., Kiss, R. G., Murphy, S. A., Wiviott, S. D., Held, P., Braunwald, E., & Sabatine, M. S.
Affiliations: Newark Beth Israel Medical Center (US)
Brigham and Women's Hospital (US)
University of Sheffield (GB)
AstraZeneca (Sweden) (SE)
Icahn School of Medicine at Mount Sinai (US)
Canisius-Wilhelmina Ziekenhuis (NL)
Grochowski Hospital (PL)
National Medical Research Center of Cardiology (RU)
Justus-Liebig-Universität Gießen (DE)
Tokai University (JP)
Universidade de São Paulo (BR)
ORCID: Bonaca, Marc P.
Bhatt, Deepak L.
Cohen, Marc
Storey, Robert F.
Magnani, Giulia
Im, Kyungah
Bengtsson, Olof
Budaj, Andrzej
Hamm, Christian
Goto, Shinya
Nicolau, José Carlos
Murphy, Sabina A.
Wiviott, Stephen D.
Sabatine, Marc S.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-05-07
Volume: 372
Issue: 19
Pages: 1791-1800
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1500857
OpenAlex: W2141358924
Cited by: 1,999
References: 32
Citations by year: 2026: 86 · 2025: 99 · 2024: 102 · 2023: 130 · 2022: 163 · 2021: 189 · 2020: 232 · 2019: 205 · 2018: 220 · 2017: 222 · 2016: 236 · 2015: 108
FWCI: 188.81
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
HAL (submittedVersion)
University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
Digital Access to Libraries (submittedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Use Siena air (University of Siena) (submittedVersion)
Funders: Japan Society for the Promotion of Science (24390202)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: ticagrelor, P2Y12 inhibitors, old myocardial infarction, dual antiplatelet therapy, long-term antiplatelet therapy, cardiovascular mortality, myocardial infarction, stroke, intracranial hemorrhage, aspirin, dose comparison, secondary prevention, bleeding risk, cardiovascular risk reduction
MeSH terms: Ticagrelor, Adenosine, Aged, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk, Intracranial Hemorrhages, Kaplan-Meier Estimate, Secondary Prevention, Purinergic P2Y Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks